|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang L and Yu J: Role of apoptosis in
colon cancer biology, therapy, and prevention. Curr Colorectal
Cancer Rep. Oct 1–2013.(Epub ahead of print). doi:
10.1007/s11888-013-0188-z. View Article : Google Scholar
|
|
3
|
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ,
Meester RG, Barzi A and Jemal A: Colorectal cancer statistics,
2017. CA Cancer J Clin. 67:177–193. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Imai Y, Ishikawa E, Asada S and Sugimoto
Y: Estrogen-mediated post transcriptional down-regulation of breast
cancer resistance protein/ABCG2. Cancer Res. 65:596–604.
2005.PubMed/NCBI
|
|
5
|
Mutoh K, Tsukahara S, Mitsuhashi J,
Katayama K and Sugimoto Y: Estrogen-mediated post transcriptional
down-regulation of P-glycoprotein in MDR1-transduced human breast
cancer cells. Cancer Sci. 97:1198–1204. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xia YZ, Yang L, Xue GM, Zhang C, Guo C,
Yang YW, Li SS, Zhang LY, Guo QL and Kong≈ LY: Combining GRP78
suppression and MK2206-induced Akt inhibition decreases
doxorubicin-induced P-glycoprotein expression and mitigates
chemoresistance in human osteosarcoma. Oncotarget. 7:56371–56382.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sasaki K, Tsuno NH, Sunami E, Tsurita G,
Kawai K, Nishikawa T, Shuno Y, Hongo K, Hiyoshi M, Kaneko M, et al:
Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on
colon cancer cells. BMC Cancer. 10:3702010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tentes IK, Schmidt WM, Krupitza G, Steger
GG, Mikulits W, Kortsaris A and Mader RM: Long-term persistence of
acquired resistance to 5-fluorouracil in the colon cancer cell line
SW620. Exp Cell Res. 316:3172–3181. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chandra R, Madan J, Singh P, Chandra A,
Kumar P, Tomar V and Dass SK: Implications of nanoscale based drug
delivery systems in delivery and targeting tubulin binding agent,
noscapine in cancer cells. Curr Drug Metab. 13:1476–1483. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ye K, Ke Y, Keshava N, Shanks J, Kapp JA,
Tekmal RR, Petros J and Joshi HC: Opium alkaloid noscapine is an
antitumor agent that arrests metaphase and induces apoptosis in
dividing cells. Proc Natl Acad Sci USA. 95:1601–1606. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Aneja R, Vangapandu SN, Lopus M,
Viswesarappa VG, Dhiman N, Verma A, Chandra R, Panda D and Joshi
HC: Synthesis of microtubule-interfering halogenated noscapine
analogs that perturb mitosis in cancer cells followed by cell
death. Biochem Pharmacol. 72:415–426. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhou J, Liu M, Luthra R, Jones J, Aneja R,
Chandra R, Tekmal RR and Joshi HC: EM012, a microtubule-interfering
agent, inhibits the progression of multidrug-resistant human
ovarian cancer both in cultured cells and in athymic nude mice.
Cancer Chemother Pharmacol. 55:461–465. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu M, Luo XJ, Liao F, Lei XF and Dong WG:
Noscapine induces mitochondria-mediated apoptosis in gastric cancer
cells in vitro and in vivo. Cancer Chemother Pharmacol. 67:605–612.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang ZR, Liu M, Peng XL, Lei XF, Zhang JX
and Dong WG: Noscapine induces mitochondria-mediated apoptosis in
human colon cancer cells in vivo and in vitro. Biochem Biophys Res
Commun. 421:627–633. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Landen JW, Lang R, McMahon SJ, Rusan NM,
Yvon AM, Adams AW, Sorcinelli MD, Campbell R, Bonaccorsi P, Ansel
JC, et al: Noscapine alters microtubule dynamics in living cells
and inhibits the progression of melanoma. Cancer Res. 62:4109–4114.
2002.PubMed/NCBI
|
|
16
|
Ke Y, Ye K, Grossniklaus HE, Archer DR,
Joshi HC and Kapp JA: Noscapine inhibits tumor growth with little
toxicity to normal tissues or inhibition of immune responses.
Cancer Immunol Immunother. 49:217–225. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ohtsubo K, Yamada T, Zhao L, Jin TF,
Takeuchi S, Mouri H, Yamashita K, Yasumoto K, Fujita N, Kitagawa H,
et al: Expression of Akt kinase-interacting protein 1, a scaffold
protein of the PI3K/PDK1/Akt pathway, in pancreatic cancer.
Pancreas. 43:1093–1100. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu R, Sato N, Yanai K, Akiyoshi T, Nagai
S, Wada J, Koga K, Mibu R, Nakamura M and Katano M: Enhancement of
paclitaxel-induced apoptosis by inhibition of mitogen-activated
protein kinase pathway in colon cancer cells. Anticancer Res.
29:261–270. 2009.PubMed/NCBI
|
|
19
|
Kuno Y, Kondo K, Iwata H, Senga T, Akiyama
S, Ito K, Takagi H and Hamaguchi M: Tumor-specific activation of
mitogen-activated protein kinase in human colorectal and gastric
carcinoma tissues. Jpn J Cancer Res. 89:903–909. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang SY, Miah A, Sales KM, Fuller B,
Seifalian AM and Winslet M: Inhibition of the p38 MAPK pathway
sensitises human colon cancer cells to 5-fluorouracil treatment.
Int J Oncol. 38:1695–1702. 2011.PubMed/NCBI
|
|
21
|
Dinicola S, Pasqualato A, Proietti S,
Masiello MG, Palombo A, Coluccia P, Canipari R, Catizone A, Ricci
G, Harrath H, et al: Paradoxical E-cadherin increase in
5FU-resistant colon cancer is unaffected during
mesenchymal-epithelial reversion induced by gamma-secretase
inhibition. Life Sci. 145:174–183. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−ΔΔC(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tamm I, Wang Y, Sausville E, Scudiero DA,
Vigna N, Oltersdorf T and Reed JC: IAP-family protein survivin
inhibits caspase activity and apoptosis induced by Fas (CD95), Bax,
caspases, and anticancer drugs. Cancer Res. 58:5315–5320.
1998.PubMed/NCBI
|
|
24
|
Fang JY and Richardson BC: The MAPK
signalling pathways and colorectal cancer. Lancet Oncol. 6:322–327.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mansouri A, Ridgway LD, Korapati AL, Zhang
Q, Tian L, Wang Y, Siddik ZH, Mills GB and Claret FX: Sustained
activation of JNK/p38 MAPK pathways in response to cisplatin leads
to Fas ligand induction and cell death in ovarian carcinoma cells.
J Biol Chem. 278:19245–19256. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chang L and Karin M: Mammalian MAP kinase
signalling cascades. Nature. 410:37–40. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guo X, Ma N, Wang J, Song J, Bu X, Cheng
Y, Sun K, Xiong H, Jiang G, Zhang B, et al: Increased p38-MAPK is
responsible for chemotherapy resistance in human gastric cancer
cells. BMC Cancer. 8:3752008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Durai R, Yang SY, Sales KM, Seifalian AM,
Goldspink G and Winslet MC: Insulin-like growth factor binding
protein-4 gene therapy increases apoptosis by altering Bcl-2 and
Bax proteins and decreases angiogenesis in colorectal cancer. Int J
Oncol. 30:883–888. 2007.PubMed/NCBI
|
|
29
|
Zamzami N, Brenner C, Marzo I, Susin SA
and Kroemer G: Subcellular and submitochondrial mode of action of
Bcl-2-like oncoproteins. Oncogene. 16:2265–2282. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jeon HK, Choi SU and Jung NP: Association
of the ERK1/2 and p38 kinase pathways with nitric oxide-induced
apoptosis and cell cycle arrest in colon cancer cells. Cell Biol
Toxicol. 21:115–125. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tomar V, Kukreti S, Prakash S, Madan J and
Chandra R: Noscapine and its analogs as chemotherapeutic agent:
Current updates. Curr Top Med Chem. 17:174–188. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
DeBono A, Capuano B and Scammells PJ:
Progress toward the development of noscapine and derivatives as
anticancer agents. J Med Chem. 58:5699–5727. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chougule MB, Patel AR, Jackson T and Singh
M: Antitumor activity of Noscapine in combination with Doxorubicin
in triple negative breast cancer. PLoS One. 6:e177332011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shen W, Liang B, Yin J, Li X and Cheng J:
Noscapine Increases the sensitivity of drug-resistant ovarian
cancer cell line SKOV3/DDP to cisplatin by regulating cell cycle
and activating apoptotic pathways. Cell Biochem Biophys.
72:203–213. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Doddapaneni R, Patel K, Chowdhury N and
Singh M: Reversal of drug-resistance by noscapine
chemo-sensitization in docetaxel resistant triple negative breast
cancer. Sci Rep. 7:158242017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Peck RA, Hewett J, Harding MW, Wang YM,
Chaturvedi PR, Bhatnagar A, Ziessman H, Atkins F and Hawkins MJ:
Phase I and pharmacokinetic study of the novel MDR1 and MRP1
inhibitor biricodar administered alone and in combination with
doxorubicin. J Clin Oncol. 19:3130–3141. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cuadrado A and Nebreda AR: Mechanisms and
functions of p38 MAPK signalling. Biochem J. 429:403–417. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Katayama K, Yoshioka S, Tsukahara S,
Mitsuhashi J and Sugimoto Y: Inhibition of the mitogen-activated
protein kinase pathway results in the down-regulation of
P-glycoprotein. Mol Cancer Ther. 6:2092–2102. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhou XW, Xia YZ, Zhang YL, Luo JG, Han C,
Zhang H, Zhang C, Yang L and Kong LY: Tomentodione M sensitizes
multidrug resistant cancer cells by decreasing P-glycoprotein via
inhibition of p38 MAPK signaling. Oncotarget. 8:101965–101983.
2017. View Article : Google Scholar : PubMed/NCBI
|
